Maria Delioukina

Pfizer (United States) — United States

Medicine · Health Sciences

16h-index1.5kcitations90works0.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(31), Advanced Breast Cancer Therapies(22), Chronic Lymphocytic Leukemia Research(21), Multiple Myeloma Research and Treatments(14), HER2/EGFR in Cancer Research(9)

Publications90 total

Abstract PS1-10-25: Pharmacodynamic effects of the first-in-class CDK4-selective inhibitor atirmociclib (PF-07220060) in combination with endocrine therapy in tumors of patients with HR+/HER2− metastatic breast cancer
Clinical Cancer Research·2026
First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation
Blood·2025
ORAL ABSTRACT: HL-998 First-in-Human, Open-Label, Phase I Study of CD30-Directed Antibody-Drug Conjugate (ADC) With a Topoisomerase 1 Inhibitor Payload, PF-08046044 (35C) in Patients With Relapsed/Refractory Lymphomas: Safety and Preliminary Efficacy From Dose Escalation
Clinical Lymphoma Myeloma & Leukemia·2025
HL-998: First-in-Human, Open-Label, Phase 1 Study of CD30-Directed Antibody-Drug Conjugate (ADC) With a Topoisomerase 1 Inhibitor Payload, PF-08046044 (35C) in Patients With Relapsed/Refractory Lymphomas: Safety and Preliminary Efficacy From Dose Escalation
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: HL-998 First-in-Human, Open-Label, Phase 1 Study of CD30-Directed Antibody-Drug Conjugate (ADC) With a Topoisomerase 1 Inhibitor Payload, PF-08046044 (35C) in Patients With Relapsed/Refractory Lymphomas: Safety and Preliminary Efficacy From Dose Escalation
Clinical Lymphoma Myeloma & Leukemia·2025
Supplementary Table S3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Supplementary Figure S3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Figure 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Supplementary Table S2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Data from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Figure 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Supplementary Figure S1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Table 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Supplementary Table S4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Table 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Supplementary Figure S4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Table 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Supplementary Figure S2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Table 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
Supplementary Table S1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
2025Open Access
page 1 of 5Next →

Frequent Co-authors

Stephen J. Forman(19), Leslie Popplewell(13), Cyrille Hulin(11), Auayporn Nademanee(11), Philippe Moreau(10), Hartmut Goldschmidt(9), Aurore Perrot(8), Jasmine Zain(8), Nizar J. Bahlis(7), Supratik Basu(7), Hareth Nahi(7), Brenda Tromp(7), Saad Z. Usmani(7), Mark Kirschbaum(7), Thierry Façon(6), Shaji Kumar(6), Torben Plesner(6), Robert Z. Orlowski(6), Hang Quach(6), Michael O’Dwyer(6)